Graybug Vision Presents Top Line Results Of Phase 1/2a ADAGIO Study At Hawaiian Eye & Retina 2019
Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019 ADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF receptors for the treatment… Read More »
- Posted on: Jan 21 2019